Trade Ideas

Actionable trade ideas with defined risk and time horizons.

Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.

Articles

6,019 total articles

Blue Owl: Redemption Shock Passed — Position for a Recovery

Blue Owl: Redemption Shock Passed — Position for a Recovery

Blue Owl (OWL) has been through a painful reset as the private credit complex re-priced over the last year. With shares trading near the low end of the 52-week range, a high quarterly distribution, and free cash flow north of $1.28B, the market appears to have priced in worst-case outcomes. This trade idea targets a recovery back toward mid-cycle m…

Arcutis: Dermatology Revenue Is Turning into a Compounding Growth Engine

Arcutis: Dermatology Revenue Is Turning into a Compounding Growth Engine

Arcutis is transitioning from pure R&D to a commercial growth story. ZORYVE posted $105.4M in Q1 2026 revenue (65% YoY) and management reaffirmed 2026 guidance of $480-495M. With pediatric label expansion, new formulations and a broader sales effort, the business is starting to compound. The setup favors a long trade with defined risk controls whil…

Keysight Q2: A Clean Beat-and-Raise Setup — Tactical Long into Results

Keysight Q2: A Clean Beat-and-Raise Setup — Tactical Long into Results

Keysight looks set to beat and raise on Q2 results thanks to sustained AI infrastructure demand, strong defense spending and healthy cash generation. The stock is extended but technicals and low short interest favor an orderly rally into an earnings-print trade. Proposed trade: enter at $360.00, stop $340.00, target $405.00 over the next 45 trading…

Buy On Holding After Q1 Beat: Margin Lift and a Cleaner Risk/Reward

Buy On Holding After Q1 Beat: Margin Lift and a Cleaner Risk/Reward

On Holding reported a solid Q1 with double-digit revenue growth, margin expansion, and a raised EBITDA guide. The shares trade well below their 52-week high, carry a $12.2B market cap, and show improving technicals. This trade idea outlines an actionable long with entry, stop, and target aimed at capturing a recovery toward renewed multiple expansi…

Pro-Dex: Attractive Fundamentals, Wait for a Pullback Before Buying

Pro-Dex: Attractive Fundamentals, Wait for a Pullback Before Buying

Pro-Dex (PDEX) looks like a fundamentally healthy small-cap: mid-teens P/E, strong ROE, positive free cash flow and low leverage. The stock has ripped above its 52-week high into thin liquidity, so the practical trade is to add on a measured pullback. Entry at $58.65, stop $52.00, target $70.00 for a mid-term (45 trading days) trade.

KLA: The Unsung Gatekeeper of 2nm - A Long Trade Around the Split

KLA: The Unsung Gatekeeper of 2nm - A Long Trade Around the Split

KLA trades like a mature tech bellwether at $1,892.80 with a market cap near $247B. Its inspection, metrology and process-control portfolio is critical to hyperscalers and foundries pushing toward 2nm nodes. Combine robust free cash flow ($4.01B), sky-high returns (ROE ~80%), and a 10-for-1 stock split announced for 06/11/2026, and you have a concr…

Why Zeta's Price No Longer Matches the Business: A Short Trade Setup

Why Zeta's Price No Longer Matches the Business: A Short Trade Setup

Zeta Global (ZETA) posts healthy free cash flow and revenue growth, but a $4.1 billion market cap, EV/EBITDA ~36 and P/S near 2.9 price the stock for flawless execution. Recent regulatory noise, mixed insider/fund flows and technical weakness make the risk-reward skewed to the downside. This is a mid-term (45 trading days) short idea with a clearly…

ORIX (IX) - Position for a Beat and Follow-Through: A Swing Trade Plan

ORIX (IX) - Position for a Beat and Follow-Through: A Swing Trade Plan

ORIX (IX) offers a pragmatic swing trade: enter around today's price to play upside from expected better-than-consensus results and constructive guidance. The company trades at a modest valuation (PE 14.3, PB 1.48) with a $41.7B market cap and improving technical momentum. Target and stop are defined to keep reward/risk favorable while acknowledgin…

Novo Nordisk: Early Payoff From the Oral Wegovy Push

Novo Nordisk: Early Payoff From the Oral Wegovy Push

Novo Nordisk's rebound is being driven by strong data and adoption for its oral Wegovy and next-gen obesity candidates. The pullback is over; fundamentals and valuation leave room for a measured long trade. Entry $46.00, stop $42.00, target $56.00 for a mid-term push tied to product uptake and continued data flow.

AI Power Bottleneck Makes Constellation Energy (CEG) a Conviction Buy

AI Power Bottleneck Makes Constellation Energy (CEG) a Conviction Buy

Constellation Energy is the U.S. nuclear backbone at the moment the market is scrambling for reliable, low-carbon megawatts to feed AI data centers. Q1 revenue and EPS beat, a completed Calpine acquisition, and explicit guidance put the company on a path to meaningful earnings growth. Given the enterprise value of roughly $105 billion, limited free…